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Summary
Combined oral contraceptives,oral hormone replacement ther-
apy and thrombophilias are recognised risk factors for venous
thromboembolism in women.The objective of this study was to
assess the risk of thromboembolism among women with throm-
bophilia who are taking oral contraceptives or hormone re-
placement therapy, conducting a systematic review and meta-
analysis. Of 201 studies identified, only nine met the inclusion
criteria. Seven studies included pre-menopausal women on oral
contraceptives and two studies included peri-menopausal
women on hormone replacement therapy. For oral contracep-
tive use, significant associations of the risk of venous throm-
boembolism were found in women with factor V Leiden (OR
15.62; 95%CI 8.66 to 28.15); deficiencies of antithrombin (OR
12.60; 95%CI 1.37 to 115.79), protein C (OR 6.33; 95%CI 1.68
to 23.87), or protein S (OR 4.88; 95%CI 1.39 to 17.10), elevated
levels of factorVIIIc (OR 8.80; 95%CI 4.13 to 18.75); and factor
V Leiden and prothrombin G20210A (OR 7.85; 95%CI 1.65 to
37.41). For hormone replacement therapy, a significant associ-
ation was found in women with factor V Leiden (OR 13.16;
95%CI 4.28 to 40.47).Although limited by the small number of
studies, the findings of this study support the presence of inter-
action between thrombophilia and venous thromboembolism
among women taking oral contraceptives. However, further
studies are required to establish with greater confidence the as-
sociations of these, and other, thrombophilias with venous
thromboembolism among hormone users.
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Introduction
Oral oestrogen use in women has been associated with increased
risk of venous thromboembolism. In premenopausal women, the
risk of venous thromboembolism has been shown to increase by
about two to six-fold during the use of combined oral contracep-
tives, and in peri- and post-menopausal women, two to four-fold
during the use of hormone replacement therapy (1).
Heritable thrombophilias include deficiencies of antithrom-
bin, protein C and protein S; and common genetic mutations
such as factor V Leiden and the prothrombin G20210A mutation
and the thermolabile variant (C677T) of the methylene tetrahy-
drofolate reductase (MTHFR) gene (where association appears
much weaker) (2). Other relatively common thrombophilias with
a combination of heritable and acquired components include
elevated plasma factor VIIIc (3), hyperhomocysteinaemia (4)
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and acquired activated protein C resistance (5). Few studies have
investigated the risk of venous thromboembolism in thrombo-
philic women who use hormone therapies. A recent UK guide-
line from the Royal College of Obstetricians and Gynaecologists
on hormone replacement therapy and venous thromboembolism
highlighted the lack of evidence in this area, and suggested that
hormone replacement therapy should not be recommended in
women with high risks such as Type 1 antithrombin deficiency,
with combined defects, or additional risk factors for venous
thromboembolism (6).
The objective of this study was to evaluate and summarise the
evidence for the association between thrombophilia and in-
creased risk of venous thromboembolism in patients who were
prescribed oral contraceptives or hormone replacement therapy.
Methods
Search strategy
An extensive search was carried out by two independent re-
viewers (OW, LR) on all major electronic databases: Medline 1966
to June 2003, BIDS (EMBASE) 1980 to June 2003, the Cumu-
lative Index to Nursing and Allied Health Literature print index
(CINAHL) 1982 to June 2003, Cochrane Database of Systematic
Reviews 1998 to June 2003, Database of Reviews of Effective-
ness (DARE) 1995 to June 2003 and Kings Fund, UK (last accessed
June 2003). Relevant keywords related to thrombophilia (throm-
bophilia, hypercoagulability, factorV, activated protein C resistance,
prothrombin, antithrombin, protein C, protein S, hyperhomocys-
teinaemia, factor VIII, lupus anticoagulant, and anticardiolipin
antibodies) combined with hormones (oral contraceptives, hormone
replacement therapy, oestrogen, progestin, medroxyprogeste-
rone, SERMS, and raloxifene), were used (as MeSH terms and
text words) to capture all potentially relevant studies. Only articles
published in English were retrieved. This strategy was supple-
mented by using the Web of Science database to generate a list of
articles that cited identified original studies. Hand searching the
abstracts of recent thrombosis conferences and the references of
all studies meeting the reference criteria was also carried out.
Inclusion and exclusion criteria
All prospective and retrospective studies were included in the re-
view if they met the following criteria:
– study population included those prescribed oral contracep-
tives or hormone replacement therapy
– clinical outcomes included measures of incidence of venous
thromboembolism events and/or mortality
– extractable data that defined categorically the presence or ab-
sence of any thrombophilic defects were available.
Data extraction
Data from studies meeting the inclusion criteria were reviewed
and extracted into pre-piloted data extraction forms indepen-
dently by the two reviewers during which the quality of the forms
was also assessed. This systematic review included a variety of
study types. In order to maintain a consistency of reporting, a
validated generic checklist designed for quantitative studies was
used to assess the quality of all the studies included in the review
(7). This checklist originally included 14 criteria, however, one
of which referred to random allocation of treatment and another
referred to blinding of subjects.These were considered not appli-
cable to observational studies and were excluded from the check-
list; therefore, the final checklist consisted of 12 items. These
items are consistent with the recommendations from the Centre
for Reviews and Dissemination (CRD) (8) and the consensus
statement of meta-analysis reporting of observational studies in
epidemiology (9). Any disagreement relating to inclusion of
studies, data extraction or quality assessment between the re-
viewers was resolved by discussion.
Data synthesis
The outcomes of interest included all confirmed venous throm-
boembolism incidence measures, including deep vein thrombo-
sis (DVT), pulmonary embolism (PE), and mortality. Each study
included in the review was summarised according to its odds
ratio, stratified by hormone use and individual thrombophilic de-
fects, both alone and in combination. Odds ratios greater than
one indicate an increased risk of venous thromboembolism-
events or mortality associated with hormone use and throm-
bophilia. Where appropriate, meta-analysis was carried out and
pooled odds ratios were calculated based on the random effect
model (DerSimonian and Laird), which accounts for inter-study
variations and provides a more conservative estimate of effect
than the fixed effect model. Potential sources of heterogeneity
were investigated and assessed using the standard chi-square test
(χ
2
). Sensitivity analysis was carried out to assess the robustness
of the results of the meta-analysis. All analyses were performed
using RevMan 4.1 (Cochrane Collaboration, Oxford, UK).
Results
Of 201 studies identified from the searches, only nine studies
met the inclusion criteria (Fig. 1). No studies of the MTHFR mu-
tation were found.Figure 1: Selection of studies for systematic review.
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Combined oral contraceptives
Six case-control studies and one retrospective cohort study on
combined oral contraceptives met the inclusion criteria for the
review (Table 1). Venous thromboembolism events observed in
1127 combined oral contraceptive users were compared with
1767 non-users.The methodological qualities of the studies were
relatively consistent (Table 1). Only one study described blinded
assessment of outcomes.
The results of the meta-analysis (Fig. 2) showed strong as-
sociations between the use of oral contraceptives and throm-
Table 1: Description of studies on thrombophilia and oral contraceptive use included in the review.
Source and
Type of Study
Participants Hormones Quality Criteria
Andersen et al (1998);
Denmark (13)
Case-control study
Cases (n = 67) – women with
spontaneous DVT or PE ident-
ified from discharge records.
Controls (n = 134) – blood do-
nors from the same region, age-
matched (2:1).
Oral contraceptives – classi-
fied into third generation
and other (i.e. first and sec-
ond generation and proges-
togen-only pill) OC.
Information on OC use
(three months prior to ad-
mission for cases) was ob-
tained from hospital records,
telephone interviews and
self-administered question-
naires.
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 = Partial
7 = No
8 =Yes
9 =Yes
10 =Yes
11 =Yes
12 =Yes
Bloemenkamp et al (1999);
The Netherlands (16)
Case-control study
Cases (n = 155) – pre-menopau-
sal women with confirmed first
deep vein thrombosis identified
from the records of anticoagu-
lation clinics.
Controls (n = 169) – friends and
acquaintances, or partners of
other patients at the clinic, with
no history of deep vein throm-
bosis, matched for age.
Oral contraceptives – classi-
fied into non-current OC
use and current OC use.
Information on OC use (one
month prior to event for
cases) was obtained from
personal interviews.
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 =Yes
7 =Yes
8 =Yes
9 =Yes
10 = Partial
11 =Yes
12 =Yes
Legnani et al (2002);
Italy (15)
Case-control study
Cases (n = 301) – women who
had at least one venous throm-
boembolism event during repro-
ductive age.
Controls (n = 650) – healthy
women of reproductive age
from the same geographical
area.
Oral contraceptives – classi-
fied according to the type of
progestin into second gener-
ation and third generation.
Information on OC use was
obtained from personal in-
terviews.
1 =Yes
2 =Yes
3 = Partial
4 =Yes
5 =Yes
6 =Yes
7 = No
8 =Yes
9 =Yes
10 = Partial
11 =Yes
12 =Yes
Martinelli et al (1999);
Italy (11)
Case-control study
Cases (n = 148) – women with
first objectively documented
DVT.
Control (n = 277) – healthy
women who were friends or
partners of referred patients in
the same 3-year study period.
Oral contraceptives – classi-
fied into first, second and
third generation.
Information on OC use at
the time of thrombosis, i.e.
until two weeks or less be-
fore the thrombotic event
(cases) or time of sampling
(controls) was recorded.
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 =Yes
7 = No
8 =Yes
9 =Yes
10 = Partial
11 =Yes
12 =Yes
Santamaria et al (2001);
Spain (10)
Retrospective cohort study
Cohort (n = 325) women from
97 families with at least two
family members identified as car-
riers of one or more thrombo-
philic factors (AT, PC, PS, FVL,
Prothrombin G20210A).
Oral contraceptives – first,
second and third generation.
Information was obtained by
questionnaires filled out dur-
ing an appointment or by a
telephone interview.
1 =Yes
2 =Yes
3 = Partial
4 =Yes
5 =Yes
6 = Partial
7 = No
8 =Yes
9 =Yes
10 = Partial
11 =Yes
12 =Yes
Quality criteria: 1 = study question sufficiently described; 2 = design evident and appropriate to answer study question; 3 = method of subject selection (and comparison group selection, if applicable) is de-
scribed and appropriate; 4 = subject (and comparison group, if applicable) characteristics sufficiently described; 5 = outcome and (if applicable) exposure measure(s) well defined and robust to measurement.mis-
classification bias; 6 = sample size appropriate; 7 = blinding of investigators; 8 = analysis described and appropriate; 9 = some estimate of variance for the main results/outcomes; 10 = controlled for confounding;
11 = results reported in sufficient detail; 12 = do the results support the conclusions. The studies by Bloemenkamp et al (1999) andVandenbroucke et al (1994) in the table refer to the same study population,
but reported theVTE risks of high FVIIIc and FVL, respectively.
Thrombophilia
FVL, AT, PC, PS
High FVIII
(≥150 IU/dl)
AT, PC, PS, APCR, FVL,
Prothrombin G20210A
Thrombophilia screen:
prothrombin
G20210A, FVL, anti-
phospholipid
syndrome, AT, PC, PS,
LA
and anticardiolipin anti-
bodies.
AT, PC, PS, FVL,
Prothrombin G20210A
Outcome Measures
VTE events
Thrombotic events were con-
firmed at diagnosis by phle-
bography, ultrasound, per-
fusion lung scan echocardio-
graphy or when the event led
to treatment with heparin or
anticoagulants.
DVT
First episode of proven DVT
diagnosed by established
objective methods.
VTE events
Objectively confirmed DVT
(confirmed by compression
ultrasonography or ve-
nography) of the lower limb,
with and without PE (confirm-
ed by ventilation perfusion
lung scan).
DVT
First, objectively documented
episode of DVT of the lower
extremities.
VTE events
Deep vein thrombosis with or
without pulmonary embolism.
Standard objective diagnostic
procedures were used for all
symptomatic women.
Results
The risk ofVTE in the presence of
heritable thrombophilia (including
FVL, AT, PC and PS) was similar for
both third generation OC users
and users of other OC (OR 52.5;
95%CI 3.7 to 738.1 and OR 63.3;
95%CI 6.2 to 648.4, respectively).
Both OC use and high FVIII levels
were shown to be associated with
increased DVT risk (OR 3.8, 95%
CI 2.4 to 6.0 and OR 4.0, 95% CI
2.0 to 8.0). The presence of both
factors had an additive effect, re-
sulted in OR 10.3 (95%CI 3.7 to
28.9).
A strong interaction between OC
use and the presence of either FVL
(OR 41.0, 95% CI 13.5 to 125) or
prothrombin G20210A (OR 58.6,
95% CI 12.8 to 276) mutations was
observed. The risk ofVTE in OC
users who had both mutations was
significantly increased (OR 86.5,
95% CI 10.0 to 747).
The most prevalent circumstantial
risk factor in patients and the only
one observed in controls was OC
use, conferred a 6-fold increased
risk of thrombosis. The risk in-
creased to OR 16.3 (95% CI 3.4 to
79.1) and OR 20.0 (95% CI 4.2 to
94.3) in OC users with prothrom-
bin G20210A and FVL, respect-
ively, indicating a multiplicative in-
teraction between the genetic risk
factors and OC use.
The risk ofVTE in prothrombin
carriers using OC was three-fold
higher (95%CI 1.3 to 6.8) than that
in non-carriers. Carriers of FVL
taking OC showed OR 1.4 (95%CI
0.6 to 3.3).
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bophilia (alone and in combination), and venous thromboembol-
ism. The odds ratios for oral contraceptive use and the risk
of venous thromboembolism ranged between 1.32 and 4.90.
Overall, the odds of developing venous thromboembolism
among oral contraceptive users were almost three times greater
than that of non-users (OR 3.10; 95% CI 2.17 to 4.42). However,
significant (p = 0.003) heterogeneity was present among the
studies.
The risk associated with thrombophilia and venous throm-
boembolism in this study population was also calculated (Fig. 2).
Positive associations between factor V Leiden and venous
thromboembolism were reported in six studies (10–15) and a
pooled odds ratio of 3.78 (95%CI 2.22 to 6.42) was observed.Al-
though no significant heterogeneity was detected (p = 0.14), the
inconsistency among the study results was moderately large
(Fig. 2). The odds of developing venous thromboembolism in
those with protein S deficiency was approximately five times
(OR 5.31; 95%CI 2.48 to 11.37) that of those without the defi-
ciency. This finding was based on data from two studies (10, 13).
No evidence of heterogeneity (p = 0.57) was detected between
the two studies. Individual studies reported the risks of venous
thromboembolism with protein C deficiency (OR 2.45; 95%CI
1.18 to 5.11) and elevated levels of factorVIIIc (OR 4.56; 95%CI
2.05 to 10.15) (10, 16). The increase in risks associated with the
combined defects of factor V Leiden and prothrombin G20210A
were reported in two studies (10, 15), and meta-analysis gave a
pooled odds ratio of OR 4.03 (95%CI 1.01 to 16.01). These
studies showed no evidence of heterogeneity (p = 0.59). The pro-
thrombin G20210A mutation and antithrombin deficiency were
described in three (10, 11, 15) and two studies (10, 13), respect-
ively. Increased risks were observed with prothrombin G20210A
(OR 1.34; 95%CI 0.81 to 2.23) and antithrombin deficiency (OR
3.18; 95%CI 0.82 to 12.29), the odds ratios were not statistically
significant. No association was observed with the combined de-
fect of prothrombin G20210A and protein C deficiency (OR
0.80; 95%CI 0.08 to 7.82). However, data were only available
from one study (10).
A supra-additive effect for risk of venous thromboembolism
was observed between the use of oral contraceptives and throm-
bophilias. The odds of developing venous thromboembolism in
those who had both risk factors were substantially amplified
compared with either of the risk factors considered alone. The
most significant increased risk was observed with factor V
Leiden and use of oral contraceptives (OR 15.62; 95%CI 8.66 to
28.15), five times that observed with either risk factor in iso-
lation. Similar, but less pronounced effects were also observed in
oral contraceptive users who had deficiencies of antithrombin,
or protein C. The combination of risk factors resulted in odds
four (OR 12.60; 95%CI 1.37 to 115.79) and two times (OR 6.33;
95%CI 1.68 to 23.87) that observed with either risk factor in iso-
lation, respectively.Test for heterogeneity was non-significant (p
= 1.00 and p = 0.40, respectively). Meta-analysis of two
studies (10, 15) showed that the use of oral contraceptives
doubled the risk of those with combined thrombophilic defects
of factorV Leiden and prothrombin G20210A but no oral contra-
ceptive use (OR 7.85; 95%CI 1.65to 37.51). No significant het-
erogeneity (p = 0.21) was detected among the results. One study
reported an association between elevated levels of factor VIIIc in
combination with oral contraceptive use and venous throm-
boembolism (OR 8.8; 95%CI 4.13 to 18.75) (16). No significant
association was observed with prothrombin G20210A (OR 6.09;
95%CI 0.81 to 45.64); or with combined defects on prothrombin
Source and
Type of Study
Participants Hormones Quality Criteria
Spannagl et al (2000);
Germany (14)
Case-control study
Cases (n = 80) – women with
DVT or PE.
Controls (n = 406) – women
randomly sampled by computer
form the population-based
BATER study database. Up to
six controls were randomly
matched per case, by age group.
Oral contraceptives – cur-
rent use and no use (never
or past use) at the time of
event or interview.
Information on OC use was
obtained by self-adminis-
tered questionnaires.
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 = Partial
7 = No
8 =Yes
9 =Yes
10 =Yes
11 =Yes
12 =Yes
Vandenbroucke et al (1994);
The Netherlands (12)
Population-based case-con-
trol study
Cases (n = 155) – pre-menopau-
sal women with confirmed first
deep vein thrombosis identified
from the records of anticoagu-
lation clinics.
Controls (n = 169) – friends and
acquaintances, or partners of
other patients at the clinic, with
no history of deep vein throm-
bosis, matched for age.
Oral contraceptives – classi-
fied into non-current OC
use and current OC use.
Information on OC use (one
month prior to event for
cases) was obtained from
personal interviews.
1 =Yes
2 =Yes
3 = Partial
4 = Partial
5 =Yes
6 =Yes
7 = No
8 =Yes
9 =Yes
10 = Partial
11 =Yes
12 =Yes
Quality criteria: 1 = study question sufficiently described; 2 = design evident and appropriate to answer study question; 3 = method of subject selection (and comparison group selection, if applicable) is de-
scribed and appropriate; 4 = subject (and comparison group, if applicable) characteristics sufficiently described; 5 = outcome and (if applicable) exposure measure(s) well defined and robust to measurement.mis-
classification bias; 6 = sample size appropriate; 7 = blinding of investigators; 8 = analysis described and appropriate; 9 = some estimate of variance for the main results/outcomes; 10 = controlled for confounding;
11 = results reported in sufficient detail; 12 = do the results support the conclusions. The studies by Bloemenkamp et al (1999) andVandenbroucke et al (1994) in the table refer to the same study population,
but reported theVTE risks of high FVIIIc and FVL, respectively.
Thrombophilia
FVL
FVL
Outcome Measures
VTE events
VTE diagnosed if clinical signs
were present and confirmed
by imaging tests and/or
treated with anticoagulants.
DVT
First episode of proven DVT
diagnosed by established ob-
jective methods.
Results
Matched, adjusted OR for idio-
pathicVTE in women without and
with FVL who used OC were 4.1
(95% CI 2.1 to 7.8) and 10.2 (95%
CI 1.2 to 88.4), respectively. The
adjusted OR for FVL carrier was
2.0 (95% CI 1.0 to 4.4). The OR
for women with FVL and OR ver-
sus no FVL and no OC was 10.2
(95% CI 3.8 to 27.6).
The risk of thrombosis among OC
users was increased four-fold (RR
3.8, 95% CI 2.5 to 6.0). The risk of
thrombosis among FVL carriers
was increased eight-fold (RR 7.9,
95% CI 3.2 to 19.4). Compared
with non-OC users not carrying
the mutation, the risk of thrombo-
sis among those with both risk fac-
tors was increased more than
30-fold (RR 34.7, 95% CI 7.8 to
154).
Table 1: Continued
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Figure 2: Odds ratios for the risk of venous thromboembolism in studies of selected thrombophilias and oral contraceptive use.
Data from only one study was available; no metaanalysis was performed.
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Figure 2: Continued. Data from only one study was available; no metaanalysis was performed.
G20210A and protein C (OR 2.39; 95% CI 0.15 to 38.85) with
oral contraceptive use. A pooled odds ratio of 4.88 (95%CI 1.39
to 17.10) was observed with protein S deficiency and the use of
oral contraceptives. However, this was lower than risk observed
with protein S deficiency in isolation (OR 5.31; 95%CI 2.48 to
11.37).
Sensitivity analysis was carried out to explore the heteroge-
neity and inconsistencies of the results of the studies included in
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the meta-analysis. All the analyses were repeated using a fixed
effect model, however, there was little change in the results. The
effect of study type was also investigated by restricting the analy-
sis to case-control studies and excluding the only cohort study
(10) in the analysis. This resulted in a modest increase in the es-
timated risk of FVL and oral contraceptive use, and the incon-
sistency among the results reported in the individual studies was
removed (OR 19.43; 95%CI 11.42 to 33.06).This restriction also
had a significant impact on the analysis on prothrombin
G20210A and oral contraceptive use. A significant increase in
risk of venous thromboembolism was estimated (OR 15.66;
95%CI 4.44 to 55.18). No evidence of heterogeneity was shown
(p = 0.22). These findings are unsurprising; due to potential as-
certainment bias, the risks reported in case-control studies have
been known to be greater than that reported in cohort studies.
Hormone replacement therapy
Two studies on HRT were included in the review (Table 2). One
was a nested case-control study of factor V Leiden (17) from two
trials (18, 19). Another case-control study (20) included factor V
Leiden and prothrombin G20210A mutation. Only four patients
carried prothrombin mutations (two cases and two controls) and
none were users of hormone replacement therapy. Therefore, no
analysis was carried out for the prothrombin G20210A mutation.
Meta-analysis for factor V Leiden, the use of hormone re-
placement therapy, and venous thromboembolism events was
conducted (Fig. 3). The results reported by both studies were
consistent and tests for heterogeneity were non-significant (p =
0.89 hormone replacement therapy, 0.77 factor V Leiden and
0.78 hormone replacement therapy and factorV Leiden).The use
of hormone replacement therapy was associated with a three-
times increased risk in venous thromboembolism events (pooled
OR 3.16; 95%CI 1.90 to 5.23). A similar effect was observed
with the presence of factor V Leiden mutation (pooled OR 3.58;
95%CI 1.43 to 8.97). Patients who had both risk factors had
much higher risk of developing venous thromboembolism
events (pooled OR 13.16; 95%CI 4.28 to 40.47).
Discussion
This review was based on literature reports that women with
thrombophilias who take hormones such as oral contraceptives
and hormone replacement therapy are at increased risk of devel-
oping venous thromboembolism. Based on the current evidence
available in the literature, the findings of this study generally
support this hypothesis, indicating that certain thrombophilias,
in particular factor V Leiden; deficiencies of antithrombin, pro-
tein C, or protein S; elevated levels of factorVIIIc and compound
heterozygosity for factor V Leiden and prothrombin G20210A
increase the risk of venous thromboembolism among users of
oral contraceptives; and also that factor V Leiden increases the
risk in users of hormone replacement therapy. While we re-
viewed only studies with hormone users, the odds ratios for the
increase in risk of venous thromboembolism were similar to
those studies of thrombophilia in the general population (2, 21).
With the exception of antithrombin deficiency, the reported
odds ratios for thrombophilic women developing venous throm-
boembolism during the use of oral contraceptives varied sub-
stantially in individual studies. For instance, the reported odds
ratios for venous thromboembolism among women with factorV
Table 2: Description of studies on thrombophilia and hormone replacement therapy use included in the review.
Source and
Type of Study
Participants Hormones Thrombophilia Outcome Measures Results Quality
Criteria
Herrington et al (2002);
US
17
Nested case-control study
Participants of the HERS and ERA trial.
Postmenopausal women, <80 years with
documented coronary artery disease.
Cases (n = 48) – women who had a throm-
botic event during the trial.
Controls (n = 112) – those who did not
have a thrombotic event.
Hormone replacement
therapy – participants in the
HERS trial received oral
conjugated equine oes-
trogen 0.625 mg plus me-
droxyprogesterone acetate
2.5 mg daily. Participants in
the ERA trial received oral
conjugated equine oes-
trogen 0.625 mg, oestrogen
plus medroxyprogesterone
acetate 2.5 mg.
FVL VTE events
A diagnosis of DVT was con-
firmed by venography, im-
pedance plethysmography, or
ultrasound. A diagnosis of PE
was confirmed by a segmen-
tal or larger ventilation/per-
fusion mismatch on a nuclear
lung scan or an intraluminal
filling by pulmonary angi-
ography.
FactorV Leiden was present in 8/48
cases and 7/112 controls (OR 3.3,
95% CI 1.1 to 9.8). In non-FVL car-
riers, the risk associated with HRT
use was significantly increased (OR
3.7, 95% CI 1.4 to 9.4). However, in
FVL carriers, the risk associated with
HRT use increased nearly six-fold (OR
5.7, 95% CI 0.6 to 53.9). The OR for
women with FVL assigned to HRT
compared with non-carriers given
placebo was 14.1 (95% CI 2.7 to
72.4).
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 =Yes
7 =Yes
8 =Yes
9 =Yes
10 =Yes
11 =Yes
12 =Yes
Rosendaal et al (2002);
UK
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Case-control study
Cases (n = 77) – women admitted with a
main diagnosis of a first episode of DVT or
PE.
Controls (n = 163) – women admitted for
diagnoses unrelated to thrombosis and
HRT. Up to two controls were chosen per
case, matched by 5-year age group, district
and date of hospitalisation.
Hormone replacement
therapy (all types) – current
users were defined as the
use of HRT at any time in
the month prior to hospital
admission.
Prothrombotic
mutations: FVL,
prothrombin
G20210A
VTE events
Idiopathic deep vein throm-
bosis and pulmonary embol-
ism, classified as definite (ob-
jectively confirmed), prob-
able, possible or other.
Among the cases, 51% were receiving
HRT at the time of thrombosis com-
pared with 24% of the control group
(OR 3.3, 95% CI 1.8 to 5.8). A pro-
thrombotic mutation (FVL or pro-
thrombin G20210A) was observed in
23% of the cases compared with 7%
of controls (OR 3.8, 95% CI 1.7 to
8.5). None of the prothrombin
G20210A carriers used HRT. Women
who had FVL and HRT use had a
15-fold increased risk of thrombosis
(OR 15.5, 95% CI 3.1 to 7.7).
1 =Yes
2 =Yes
3 =Yes
4 =Yes
5 =Yes
6 =Yes
7 = No
8 =Yes
9 =Yes
10 = No
11 =Yes
12 =Yes
Quality criteria: 1 = study question sufficiently described; 2 = design evident and appropriate to answer study question; 3 = method of subject selection (and comparison group selection, if applicable) is de-
scribed and appropriate; 4 = subject (and comparison group, if applicable) characteristics sufficiently described; 5 = outcome and (if applicable) exposure measure(s) well defined and robust to measure-
ment.misclassification bias; 6 = sample size appropriate; 7 = blinding of investigators; 8 = analysis described and appropriate; 9 = some estimate of variance for the main results/outcomes; 10 = controlled for
confounding; 11 = results reported in sufficient detail; 12 = do the results support the conclusions
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Figure 3: Odds ratios for the risk of venous thromboembolism in studies of selected thrombophilias and hormone replacement
therapy use. Data from only one study was available; no metaanalysis was performed.
Leiden who were oral contraceptive users ranged from 5.86 (10)
to 34.72 (12). One reason may be different inclusion criteria: the
studies of Legnani (15) and Santamaria (10) were performed on
women referred for a thrombophilia workup and women with
familial thrombophilia respectively; such women may have a
higher risk of thrombosis (22). The pooled odds ratio estimated
by our meta-analysis was 15.62, substantially less than the most
commonly cited odds ratio first reported by Vandenbroucke et al
(12). Our result is similar to a previous, smaller meta-analysis of
three studies (OR 10.25) (23). This meta-analysis also reported
similar results to the present study for prothrombin G20210A
(OR 7.14) and for its combination with factor V Leiden (OR
16.97) (23). The variations observed in other thrombophilic de-
fects, such as deficiencies of protein C and protein S and com-
bined thrombophilic defects, may be explained by the study type
as the results were pooled from both case-control and cohort
studies.
The thrombophilias described in this study represented pri-
marily heterozygous mutations. Four studies did not define the
genotypes (11, 13, 14, 17), one study presented summed data for
both heterozygous and homozygous mutations (10), two studies
excluded all homozygous carriers (12, 15), and one study had no
homozygous carriers (20). Separate analysis on individual geno-
types was not carried out due to the lack of data. Vandenbroucke
et al have estimated, based on a multiplicative effect, that the risk
increase for homozygous factor V Leiden among oral contracep-
tive users may be more than 100-fold (12).
The type of combined oral contraceptive has been shown to
be an important factor in determining the risk increase in venous
thromboembolism. Third generation oral contraceptives have
been shown to incur greater risks than other classes of oral
contraceptives (1, 24). Four of the studies included in this review
described the distinction between third generation and other oral
contraceptives (10, 11, 13, 15), but separate data were presented
only in one study (13). Although this study showed that third
generation oral contraceptives had a greater effect than other oral
contraceptives on the risk of venous thromboembolism (OR 20.9
compared with 7.1), this effect was no longer observed in women
with the factor V Leiden mutation. The risk of venous throm-
boembolism was greater in first and second generation oral
contraceptive users compared with third generation oral contra-
ceptives (OR 64.7 compared with 29.6).
Few studies have investigated the relationship between
thrombophilias and venous thromboembolism in users of hor-
mone replacement therapy. Since no data were available on
thrombophilias other than factor V Leiden, the results of this re-
view have been restricted to women with factor V Leiden, who
had a very similar increase in risk of venous thromboembolism
in two studies (19, 20). One study, not included in this review due
to the lack of extractable data (25) also reported significant in-
creases in the risk of venous thromboembolism in women with
high levels of factor IX (OR 2.34), increased resistance to acti-
vated protein C (OR 4.06), decreased antithrombin (OR 3.33) or
decreased protein C (OR 2.93). The risk of venous thromboem-
bolism in women using transdermal hormone replacement ther-
apy has been shown to be lower than that observed with oral
preparations (26–28). However, to date, no data relating to trans-
dermal hormone replacement therapy users with thrombophilia
have been presented in the literature.
This systematic review highlights the small number of rel-
evant published studies available for inclusion in meta-analyses.
Although only studies published in English were included in this
review, it is unlikely that this would result in the exclusion of im-
portant studies and the introduction of significant selection bias
(29). In addition, the literature search indicated that non-English
studies are not particularly prevalent in this area. The majority of
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studies identified were case-control studies, which may be
biased with regards to selection of controls. The confidence in-
tervals of the estimated odds ratios for thrombophilias such as
deficiencies of antithrombin, proteins C or S, and the combined
thrombophilic defects among oral contraceptive users are large,
and hence the results should be interpreted with caution. Fur-
thermore, comparisons of thrombophilia, the use of oral oes-
trogen preparations and the risk of venous thromboembolism are
indirect. The large observed differences between the venous
thromboembolism odds ratios for some thrombophilias, and
thrombophilia plus oral oestrogen use, had limited sample size,
hence formal analyses were not feasible. We therefore recom-
mend that larger studies, including more thrombophilic patients
and controls, are required to provide more reliable estimates.
Meanwhile, it seems reasonable to conclude that the interaction
of oral contraceptives and factor V Leiden were supra-additive,
because the lower 95% CI (8.7) of the meta-analysis exceeds the
sum of risks (5.9).
It has been suggested that women might be screened for
thrombophilia prior to prescribing hormone preparations, in-
cluding combined oral contraceptives (30) and hormone replace-
ment therapy (20). However, due to the low incidence of venous
thromboembolism in these populations of women, the absolute
risk is low and mass screening strategies are unlikely to be effec-
tive. Important issues such as absolute risk, acceptability, psy-
chological consequences deriving from the diagnosis of throm-
bophilia, potential consequences of false positive and false
negative results, and economic issues, need all to be taken into
account. We are currently preparing a further paper on screening,
which addresses some of these considerations.
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